US EditionPfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer (NYSE:PFE)
Pfizer ends all trials of inclacumab after Phase III trial fails to reduce painful vaso-occlusive crises in sickle cell patients, affecting global clinical programs.
5 Articles
5 Articles
Pfizer Gets Another Dose of Disappointment as Sickle Cell Disease Drug Fails Pivotal Test
Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests showed higher rates of complications and deaths for that sickle cell disease drug. The post Pfizer Gets Another Dose of Disappointment as Sickle Cell Disease Drug Fails Pivotal Test appeared first on MedCity News.
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease. PFE shares are consolidating after recent moves. Track the latest developments here. Sickle cell disease is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen. It causes red blood cells…
MARAC Statement: Pfizer Inclacumab Announcement - Sickle Cell Disease Association of America Inc.
August 15, 2025 – In a statement issued today, Pfizer announced the results of their Phase 3 THRIVE-131 study evaluating inclacumab. Although inclacumab was generally well tolerated in THRIVE-131, the study results concluded that inclacumab “did not meet its primary endpoint of significant reduction in the rate of vaso-occlusive crises (VOCs) in participants receiving inclacumab versus placebo every 12 weeks.” The Medical and Research Advisory…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
